Rhabdomyosarcoma

What is Rhabdomyosarcoma?

Rhabdomyosarcoma is a rare type of soft tissue cancer that develops from muscle cells or cells that normally become muscles. It primarily affects children and adolescents, though it can occasionally occur in adults. This aggressive cancer can develop anywhere in the body but most commonly appears in the head and neck region, genitourinary tract, arms, legs, and trunk. With an incidence of approximately 4.5 cases per million children annually, rhabdomyosarcoma accounts for about 3-4% of all childhood cancers, making it the most common soft tissue sarcoma in pediatric patients.

Key statistics

Symptoms

Painless enlarging mass, difficulty swallowing, urinary problems, nosebleeds, eye protrusion, limb swelling, abdominal pain, constipation.

The symptoms of rhabdomyosarcoma vary significantly depending on the tumor’s location. The most common early sign is a painless, enlarging mass that parents or patients notice growing over weeks to months. In head and neck tumors, symptoms may include persistent nasal congestion, nosebleeds, difficulty swallowing, ear pain, or eye protrusion. Genitourinary rhabdomyosarcomas can cause urinary difficulties, blood in urine, constipation, or a visible mass in the genital area. Tumors in the arms or legs typically present as growing lumps that may eventually cause pain or interfere with movement. Abdominal tumors can cause persistent abdominal pain, nausea, vomiting, or changes in bowel habits. Unlike many other conditions, fever and weight loss are not typically early symptoms, which can sometimes delay diagnosis as the masses may initially appear benign.

Causes and risk factors

Rhabdomyosarcoma is mostly sporadic, meaning it occurs randomly without a clear inherited pattern. The exact cause remains unknown in most cases, but researchers believe it results from genetic mutations that occur during fetal development or early childhood, causing muscle-forming cells to grow uncontrollably instead of developing normally.

Submit Your Paper

Several genetic conditions increase the risk, including Li-Fraumeni syndrome, neurofibromatosis type 1, Beckwith-Wiedemann syndrome, and Costello syndrome. Environmental risk factors are not well-established, though some studies suggest potential associations with parental drug use, radiation exposure during pregnancy, or certain parental occupational exposures. Children born with birth defects of the central nervous system or genitourinary tract may have slightly elevated risk. Unlike many adult cancers, lifestyle factors do not appear to influence rhabdomyosarcoma development.

Prevention

There is no known way to prevent rhabdomyosarcoma since most cases occur sporadically without identifiable environmental triggers. For families with known genetic syndromes that increase risk, genetic counseling is recommended to discuss surveillance strategies and family planning options. Prenatal genetic testing may be available for families with hereditary cancer syndromes. Regular medical checkups can help ensure early detection if symptoms develop, but routine screening for rhabdomyosarcoma in asymptomatic children is not recommended due to its rarity.

Complications

Without treatment, rhabdomyosarcoma grows rapidly and spreads to other parts of the body, particularly the lungs, bone marrow, and lymph nodes, leading to death within months. Even with treatment, complications can include treatment-related side effects such as hearing loss, growth problems, secondary cancers, heart problems, and fertility issues from chemotherapy and radiation. Surgical complications depend on tumor location and may include functional impairment, cosmetic changes, or organ dysfunction. Long-term survivors require lifelong monitoring for treatment-related complications and potential cancer recurrence.

Diagnosis

Diagnosis begins with a thorough physical examination and medical history. Imaging studies are crucial and typically include CT scans, MRI, and chest X-rays to determine tumor size, location, and potential spread. A tissue biopsy is essential for definitive diagnosis, where pathologists examine the tumor cells under a microscope and perform special stains and molecular testing to confirm rhabdomyosarcoma and determine the specific subtype.

Additional staging studies include bone marrow biopsy, bone scans, and sometimes PET scans to determine if the cancer has spread. Genetic testing of the tumor tissue helps classify the specific subtype (embryonal, alveolar, or pleomorphic), which influences treatment decisions. Blood tests check overall health and organ function before treatment begins. The entire diagnostic process typically takes 1-2 weeks, during which families often experience significant anxiety while awaiting results.

Treatment

Treatment typically involves a multimodal approach combining chemotherapy, surgery, and radiation therapy. The specific treatment plan depends on the tumor’s location, size, subtype, and stage at diagnosis.

Chemotherapy forms the backbone of treatment and usually includes vincristine, dactinomycin, and cyclophosphamide (VAC regimen). For higher-risk cases, additional drugs such as ifosfamide, etoposide, or doxorubicin may be added. Treatment typically lasts 6-12 months.

Surgery aims to remove the tumor completely when possible, though this depends heavily on location. In some cases, initial surgery may not be feasible, and chemotherapy is given first to shrink the tumor before attempting surgical removal.

Radiation therapy is often used for tumors that cannot be completely removed surgically or for certain high-risk cases. Newer techniques like proton beam therapy may reduce side effects in some patients.

Prognosis

The overall 5-year survival rate for rhabdomyosarcoma is approximately 70-75%, but this varies significantly based on several factors. Children with localized, completely resectable tumors have survival rates exceeding 90%, while those with metastatic disease at diagnosis have survival rates of 20-30%. The tumor subtype also influences prognosis, with embryonal rhabdomyosarcoma generally having better outcomes than alveolar subtypes.

Age at diagnosis affects prognosis, with very young children (under 1 year) and adolescents typically having somewhat worse outcomes than school-age children. Tumor location is also important, with orbital and genitourinary tumors generally having better prognoses than extremity or parameningeal tumors. Most relapses occur within the first two years after treatment, and long-term survivors typically maintain good quality of life, though they require ongoing monitoring for treatment-related late effects.

Quality of life

During treatment, children typically need to limit exposure to crowds and sick contacts due to chemotherapy-induced immune suppression. Maintaining good nutrition can be challenging due to treatment side effects, and nutritionist consultation is often helpful. Many children can continue some schooling with accommodations, and maintaining social connections with friends and family is important for emotional well-being.

Physical activity should be adapted based on treatment phase and tumor location, but gentle exercise is generally encouraged when possible. Sleep patterns may be disrupted by hospital stays and treatment side effects. Mental health support, including counseling and support groups, can help families cope with the emotional challenges of cancer treatment.

After treatment completion, most survivors can return to normal activities, though some may have physical limitations depending on their treatment. Regular follow-up care is essential to monitor for potential late effects and ensure optimal long-term health and development.

Pregnancy and fertility

Rhabdomyosarcoma rarely occurs during pregnancy, but when it does, treatment decisions must balance maternal cancer treatment needs with fetal safety. Some chemotherapy agents may be given during the second and third trimesters, though treatment may need to be delayed or modified.

For survivors, fertility may be affected by previous chemotherapy or radiation treatments, particularly those involving the pelvic area. Both male and female survivors should discuss fertility preservation options before treatment begins when age-appropriate. Genetic counseling is recommended for survivors planning families, especially those with underlying genetic syndromes.

Children

Since rhabdomyosarcoma primarily affects children, pediatric considerations are central to care. Treatment is typically provided at specialized pediatric cancer centers with multidisciplinary teams including pediatric oncologists, surgeons, radiation oncologists, and support staff.

Children may need educational accommodations during treatment, and many hospitals provide school programs. Siblings also need support during this challenging time. Growth and development monitoring is crucial both during and after treatment, as chemotherapy and radiation can affect normal development. Psychological support helps children understand their illness in age-appropriate ways and cope with treatment-related stress.

Long-term follow-up is essential to monitor for treatment late effects and ensure proper growth and development as children transition into adulthood.

When to see a doctor

Seek immediate medical evaluation for any unexplained, growing mass in a child, especially if it appears in the head and neck region, genitourinary area, or extremities. Other warning signs include persistent nosebleeds, eye protrusion, difficulty swallowing, urinary problems, or abdominal masses.

While many childhood lumps and bumps are benign, any mass that grows over several weeks or is larger than 2 centimeters should be evaluated promptly. Parents should trust their instincts if something seems abnormal and seek medical attention rather than waiting to see if symptoms resolve on their own.

Regional context

Limited specific data exists for rhabdomyosarcoma prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean. The condition likely occurs at similar rates as globally reported, but regional cancer registries may not consistently capture rare pediatric cancers. We invite healthcare professionals and researchers from these regions to contribute epidemiological data and treatment experiences to the Global Medical Journal to better understand regional patterns and improve care for children with rhabdomyosarcoma.

Research and clinical trials

Current research focuses on developing targeted therapies based on specific genetic mutations found in rhabdomyosarcoma cells. Immunotherapy approaches, including checkpoint inhibitors and CAR-T cell therapy, are being investigated. Novel drug combinations and precision medicine approaches based on tumor molecular profiling show promise.

Recent breakthroughs include better understanding of the genetic drivers of different rhabdomyosarcoma subtypes, leading to more targeted treatment approaches. Researchers are also working on reducing treatment-related side effects while maintaining cure rates.

Families can search for clinical trials at ClinicalTrials.gov or through their treatment center. Participation in clinical trials may provide access to promising new treatments while contributing to research that benefits future patients.

Frequently asked questions

Is rhabdomyosarcoma hereditary?

Most cases are sporadic and not inherited. However, about 5-10% of cases occur in children with genetic syndromes like Li-Fraumeni syndrome or neurofibromatosis type 1.

What is the difference between embryonal and alveolar rhabdomyosarcoma?

These are the two main subtypes. Embryonal rhabdomyosarcoma is more common in younger children and generally has a better prognosis, while alveolar rhabdomyosarcoma often has specific genetic changes and may be more aggressive.

Can rhabdomyosarcoma be cured?

Yes, approximately 70-75% of children with rhabdomyosarcoma can be cured with appropriate treatment. Cure rates are highest when the cancer is detected early and has not spread.

How long does treatment take?

Treatment typically lasts 6-12 months, depending on the specific protocol. This includes multiple cycles of chemotherapy, surgery when appropriate, and possibly radiation therapy.

What are the long-term effects of treatment?

Potential long-term effects include hearing loss, growth problems, heart issues, secondary cancers, and fertility problems. Regular follow-up care helps monitor and manage these potential complications.

Support and resources

• American Cancer Society – Comprehensive cancer information and support
• St. Jude Children’s Research Hospital – Pediatric cancer treatment and research
• Sarcoma Foundation of America – Sarcoma-specific advocacy and research
• National Organization for Rare Disorders (NORD) – Rare disease support and advocacy
• Orphanet – Rare disease information portal
• EURORDIS – European rare disease patient advocacy
• Children’s Oncology Group – Pediatric cancer research consortium

Related conditions

• Ewing sarcoma – Another type of pediatric sarcoma
• Osteosarcoma – Bone cancer affecting children and teens
• Li-Fraumeni syndrome – Genetic cancer predisposition syndrome
• Neurofibromatosis type 1 – Genetic condition increasing sarcoma risk
• Soft tissue sarcoma – Broader category of connective tissue cancers

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.